Delivery Order SPE2DB22D3016-SPE2DB25FBDK8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,641.03 to AmerisourceBergen Drug Corp for the supply of Kerendia 10 mg tablets (30-count) on July 24, 2025, with completion expected by July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Kerendia is a prescription medication used in the treatment of chronic kidney disease and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Kerendia 10 mg tablets (30-count packaging) with a ceiling value of $2,330.76. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 4, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,344.93 to AmerisourceBergen Drug Corp for Kerendia 10 mg tablets (30-count package) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical...
- The Defense Logistics Agency awarded a delivery order valued at $12,842.64 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Kerendia 10 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, and performance will be completed by August 14, 2025, at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a $3,830.45 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Kerendia 10 mg tablets (30-count units). This non-set-aside competitive award is scheduled for completion by August 14, 2025, with performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Kerendia is a prescription medication used in the treatment of chronic kidney disease, reflecting the federal government's ongoing...
- The Defense Logistics Agency awarded a $1,930.67 delivery order to AmerisourceBergen Drug Corp for KERENDIA 10 mg tablets (30-count) on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be performed at AmerisourceBergen's corporate...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication KERENDIA 10 MG TABLET 30S. The contract is a firm fixed-price delivery order with a ceiling value of $2,576.92 and a period of performance through November 25, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a $2,687.81 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Kerendia 10 mg, a pharmaceutical product used in the treatment of chronic kidney disease. This competitively awarded, firm fixed-price contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Kerendia 10 mg tablets in a quantity of 30 units. This firm fixed-price delivery order, valued at $6,857.16, was competitively awarded with no set-aside designation and is scheduled for completion by August 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Kerendia 10 mg tablets (90-count units) with a ceiling value of $6,552.19. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and is classified as a non-set-aside contract, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBDK8Delivery Order
This delivery order, awarded July 29, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides 30 tablets of Kerendia 20 mg with a contract ceiling value of $3,042.18 and a firm fixed price structure. The order is scheduled for completion by July 30, 2025, and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This is an unset-aside, competitively awarded contract representing a routine pharmaceutical procurement to support federal medical supply needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for the Defense Health Agency and military healthcare systems, supplying a comprehensive range of brand-name and generic medications across multiple therapeutic domains. The Kerendia prescription medication supports the company's ongoing role in providing pharmaceutical commodities to federal healthcare programs through the DLA's Medical Supply Chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/29/25 |